Lightcalls.com
 

The Canadian Accounting Standards B...

The Canadian Accounting Standards Board (AcSB) issued fresh accounting standards for financial instruments onward January 27, 2005, that will impact virtually each entity in Canada, small and large. Despite the lengthiness of these just discovered standards, their impact on many entities will be unobtrusive In some cases, however, the strange standards will require entities to make significant accounting changes. All entities are therefore encouraged to promptly assess the compass to which these standards will affect them.

The recent standards are a culmination of many years of consultation with Canadian constituents and international standard setter Having explored several approaches to accounting for financial instruments, the AcSB has produc standards that will enhance the understandability of financial statements, are practical, and are harmonized with those of international partners.

The AcSB immediately has standards in place for disclosures about an entity's use of financial instruments and for the presentation of financial instruments when included in the balance sheet. Until now, however, no AcSB standards have comprehensively addressed when an entity should recognize a financial instrument forward its balance sheet, or to what degree it should measure this financial instrument one time recognized. The new standards will fill this "gap in GAAP."



New CICA Handbook sections

The just discovered standards comprise three new Handbook sections:

* Section 3855: Financial Instruments - Recognition and Measurement

This section will probably affect all entities to a degree, as it prescribes when a financial instrument is to be recognized forward the balance sheet and at what amount-sometimes using fair value; other times using cost-based measures. It also specifies for what reason financial instrument gains and losse are to be presented

* Section 3865: Hedges

Application of this section is optional. section 3865 provides alternative treatments to section 3855 for entities that select to designate qualifying transactions as hedges for accounting drifts It builds on existing Accounting Guideline AcG-13 (Hedging Relationships) and section 1650 (Foreign circulation Translation) by specifying how hedge accounting is applied and what corresponding disclosures are necessary.

* Section 1530: Comprehensive Income

This section introduces a of recent origin requirement to temporarily present certain gains and losse outside snare income.

A number of significant consequential amendments have been made to other Handbook sections.

Impact forward accounting

Financial instruments include accounts receivable and payable: loans; investments in debit and equity securities (including denomination deposits, guaranteed investment certificates, investments in used by all shares, etc.); and derivative contracts like as forwards, swaps, and options. In many cases, there will be little change from popular accounting. For example, an entity with no financial instruments other than cash, accounts receivable, accounts payable, and arms'-length debit will find little, if any, difference in accounting for these instruments. at contrast, however, an entity with investments in usual shares or derivatives, or that trades other signs of financial instruments will probably be significantly affected.

Implementation guidance

Recognizing that any entities may find the strange sections daunting, the AcSB has established a Financial Instruments Working assign places to which is charged with assisting in the disentanglement of implementation guidance. AcSB staff members also await to issue materials that will facilitate understanding the just discovered requirements-for example, articles in the November and December 2004 issues of

CAmagazine (www.camagazine. com/index.cfm) explain by what mode one might go about preparing to adopt the recent standards.

The mandatory effective date is for annual and interim periods in fiscal years beginning in succession or after October 1, 2006 (in many cases this will mean application to calendar years beginning forward January 1, 2007). However, early adoption is permitted. While the mandatory effective date might look some way off and comparative figures will not be affected, significant implementation planning may be necessary for larger entities that make extensive use of financial instruments. These entities are encouraged to not delay in reviewing the fresh standards and considering the inferences for their organizations.

Further information about the of the present day standards and the related implementation guidance is available onward the Financial Instruments project page of the AcSB website at: www.acsbcanada.org.

Please contact AcSB staff members Ian Hague (416-204-3270/email: ian.hague@cica. ca) or Kate Ward (416-204-3437/email: kate.ward@cica.ca) if you require any additional information.

Ian PN Hague is a principal responsible for the Accounting Standards Board contrive on financial instruments.

Copyright Institute of Chartered Accountants of British Columbia Feb/Mar 2005

Provided at ProQuest Information and Learning Company. All rights Reserved



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.